Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C32H35N7O4 · 2HCl
CAS Number:
Molecular Weight:
654.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(NCC1=CC=C(C=C1C)C(N2CC3=C(NC4=CC=CC=C24)N(N=C3)C)=O)N5CCN(CC5)CC6=CC(O)=CC(O)=C6
InChI
1S/C32H35N7O4.2ClH/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22;;/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43);2*1H
InChI key
OTFWXMFLPMUDFP-UHFFFAOYSA-N
Biochem/physiol Actions
Non-peptide oxytocin receptor (OTR) agonist and vasopressin V1a receptor (V1aR) antagonist.
WAY-267464 is a non-peptide drug with a novel mechanism of action (MOA) to treat psychosis and schizophrenia.
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yamei Tang et al.
Neuropharmacology, 77, 277-284 (2013-10-24)
Oxytocin (OT) was reported to affect cognitive and emotional behavior by action in ventral tegmental area (VTA) and other brain areas. However, it is still unclear how OT activates VTA and related midline nucleus. Here, using patch-clamp recording, we studied
Emma J Campbell-Smith et al.
Learning & memory (Cold Spring Harbor, N.Y.), 22(5), 247-257 (2015-04-17)
The present study investigated how oxytocin (OT) signaling in the central (CeA) and basolateral (BLA) amygdala affects acquisition, expression, and extinction of context-conditioned fear (freezing) in rats. In the first set of experiments, acquisition of fear to a shocked context
William T Jorgensen et al.
European journal of medicinal chemistry, 143, 1644-1656 (2017-11-12)
WAY-267,464 (1) and twelve conformationally rigid analogues (3a-f-4a-f) were synthesised, characterised and evaluated in cellular assays with the aim of systematically exploring interactions with the oxytocin receptor (OTR). Each analogue was evaluated in radioligand binding displacement assays at both human
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2223-5MG | 04061835494712 |
| SML2223-25MG | 04061835494705 |